”a phase 3 company priced like a phase 2 company”.
that’s because it is a phase 2 company.
this asset had negligible data in the old phase 2 it’s almost pointless. So the part 1 of this current trial first 70 patients that takes it to the mid Mar futility analysis is effectively the phase 2 that was never done for this asset.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
54.0¢ |
Change
0.005(0.93%) |
Mkt cap ! $324.0M | |||
| Open | High | Low | Value | Volume |
| 53.5¢ | 54.5¢ | 52.5¢ | $699.7K | 1.314M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5582 | 53.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 41732 | 2 |
View Market Depth
| Last trade - 16.10pm 23/07/2025 (20 minute delay) ? |
| DXB (ASX) Chart |